Normal Saline Versus Heparin Flush for Maintaining Central Venous Catheter Patency During Apheresis Collection of Peripheral Blood Stem Cells (PBSC)
Overview
Affiliations
Thrombotic occlusion is frequently a complication of central venous catheters (CVCs). The original designers and producers of CVCs recommended heparin flush regimens to prevent thrombosis and maintain patency. This has become standard practice although no studies have demonstrated a relationship between heparin flushing and reduction of catheter thrombosis. Many consider the routine use of heparin flushing innocuous. However, serious complications including drug interactions and heparin induced thrombocytopenia and thrombosis syndrome (HITS) have been reported in association with heparin flushing. Numerous studies comparing heparin to saline flushing in peripheral devices suggest equal rates of thrombotic occlusions. The purpose of this study was to examine the incidence of thrombotic occlusions in CVCs using heparin compared to saline flushing. The study involved 78 cancer patients undergoing apheresis collection for peripheral blood stem cells; 29 received saline flushes and 49 received heparin (100 U/ml of saline) flushes. Study endpoints included slow apheresis flow rate (< 50 ml/min), urokinase use for thrombolysis, and radiographic evidence of catheter thrombosis. No significant differences were found for any endpoint between the two groups. These findings suggest saline may be as effective as heparin for maintaining patency of CVCs.
Autoimmune Heparin-Induced Thrombocytopenia.
Warkentin T J Clin Med. 2023; 12(21).
PMID: 37959386 PMC: 10649402. DOI: 10.3390/jcm12216921.
Wo Y, Brisbois E, Wu J, Li Z, Major T, Mohammed A ACS Biomater Sci Eng. 2017; 3(3):349-359.
PMID: 28317023 PMC: 5351555. DOI: 10.1021/acsbiomaterials.6b00622.
Thrombolytic therapy for central venous catheter occlusion.
Baskin J, Reiss U, Wilimas J, Metzger M, Ribeiro R, Pui C Haematologica. 2011; 97(5):641-50.
PMID: 22180420 PMC: 3342964. DOI: 10.3324/haematol.2011.050492.
Central venous port systems as an integral part of chemotherapy.
Teichgraber U, Pfitzmann R, Hofmann H Dtsch Arztebl Int. 2011; 108(9):147-53.
PMID: 21442071 PMC: 3063378. DOI: 10.3238/arztebl.2011.0147.
Baskin J, Pui C, Reiss U, Wilimas J, Metzger M, Ribeiro R Lancet. 2009; 374(9684):159-69.
PMID: 19595350 PMC: 2814365. DOI: 10.1016/S0140-6736(09)60220-8.